Vemuri Praveen Kumar; Assistant Proffesor *, and Mamidi Sai Ratna Mounica, Department of Biotechnology,have authoured a paper in International Journal

Abstract: Immunologic approaches to cancer therapy rely on two distinct capabilities of the immune system: targeting the tumor micro environment by recognising molecules expressed to a greater extent on tumour cells than normal cells and generating immune responses that can kill tumor cells.Immunocytokines, which are fusion proteins composed of a recombinant monoclonal antibody and a cytokine, capitalise on both of these capabilities by combining the ability of tumour-specific antibodies selectively to target tumours with the broad-based immunomodulatory activities of cytokines. This review hypothesises the rationale for development of immunocytokines for cancer and discusses preclinical and clinical data on specific immunocytokines being investigated as potential cancer therapies.

Keywords: cytokine; cancer; immunocytokine; monoclonal antibody; aldesleukin; tumour; microenvironment; IL-2; hu14.18-IL-2; huKS-IL-2.